IC43 + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pseudomonas Aeruginosa Infection
Conditions
Pseudomonas Aeruginosa Infection
Trial Timeline
Mar 1, 2012 → Dec 1, 2015
NCT ID
NCT01563263About IC43 + Placebo
IC43 + Placebo is a phase 2/3 stage product being developed by Valneva SE for Pseudomonas Aeruginosa Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01563263. Target conditions include Pseudomonas Aeruginosa Infection.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01563263 | Phase 2/3 | Completed |
| NCT00876252 | Phase 2 | Completed |
| NCT00778388 | Phase 1 | Completed |
Competing Products
8 competing products in Pseudomonas Aeruginosa Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0292 | AstraZeneca | Phase 2 | 52 |
| tobramycin + tobramycin | Novartis | Phase 3 | 77 |
| Tobramycin inhalation powder | Novartis | Phase 3 | 77 |
| TIS or TIP | Novartis | Approved | 85 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Ciprofloxacin (Cipro, BAYQ3939) | Bayer | Phase 1 | 30 |
| Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | Insmed | Phase 3 | 74 |
| TOBI® PODHALER® + TOBI® + Bethkis® + Cayston® | Viatris | Pre-clinical | 20 |